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The COVID-19 pandemic that attacks the world has made the attention of all medical personnel focused on this disease. 
The clinical picture is similar to other infectious diseases such as malaria, dengue, influenza, etc., which often leads to 
misdiagnosis. We report the case of a man, 31 years old, with a history of travel and complaints of high fever persisting 
for more than 7 days. On physical examination, the temperature was 39-40 C, others were within normal limits. Initial 
platelet count was 69 x 103/µL, leukocytes was 15.52 x 109/L, CRP was 96 mg/L. The blood smear found Plasmodium 
falciparum, and PCR SARS-CoV-2 was positive. Chest X-ray showed pneumonia. Dihydroartemisinin-piperaquine 
and primaquine therapies were administered for malaria, as well as favipiravir, azithromycin, and other symptomatic 
therapy for COVID-19. Platelets decreased to 38 x 103/µL while D-dimer level increased (> 20 mg/L). Anticoagulant 
was delayed. On monitoring after therapy, the platelets returned to normal, the D-dimer level decreased, and there was 
no bleeding. The co-infectious conditions of malaria and COVID-19 should be suspected in patients with suggestive 
symptoms and travel history from endemic areas, therefore both examinations should be performed. This co-infection 
has the potential to cause hyper inflammation and hypercoagulation and this is associated with a poor prognosis. 
Appropriate treatment is needed. 
 




Pandemi COVID-19 yang menyerang dunia telah membuat perhatian seluruh tenaga medis terfokus pada penyakit ini. 
Gambaran klinisnya yang mirip dengan penyakit infeksi lain seperti malaria, dengue, influenza, dll, sering menyebabkan 
kesalahan diagnosis. Kami melaporkan kasus seorang laki-laki, 31 tahun, dengan riwayat perjalanan dan keluhan demam 
tinggi menetap lebih dari 7 hari. Pemeriksaan fisik didapatkan suhu 39-40 C, lain-lain dalam batas normal. Hitung 
trombosit awal 69 x 103/µL, leukosit 15.52x109/L, CRP 96 mg/L. Apusan darah dijumpai Plasmodium falciparum, dan 
PCR SARS-CoV-2 positif. Rontgen thorax menggambarkan pnemonia. Terapi dihidroartemisinin-piperakuin dan 
primakuin untuk malaria, serta favipiravir, azitromisin dan terapi simptomatik lain diberikan untuk COVID-19. Trombosit 
sempat turun hingga 38 x 103/µL dan peningkatan D-dimer >20 ug/mL. Antikoagulan ditunda. Setelah pemantauan, 
trombosit kembali ke normal, D-dimer turun, dan tidak dijumpai perdarahan. Kondisi ko-infeksi malaria dan COVID-19 
harus dicurigai pada pasien dengan gejala yang mendukung dan riwayat perjalanan dari daerah endemis, sehingga harus 
dilakukan pemeriksaan laboratorium untuk memeriksa kedua penyakit ini. Ko-infeksi ini berpotensi menimbulkan 
hiperinflamasi dan hiperkoagulasi dan ini dihubungkan dengan prognosis yang buruk. Terapi yang tepat dibutuhkan. 
 
Kata kunci: SARS CoV-2, Plasmodium, trombosit 
 





Since the declaration as a global health 
emergency on January 30, 2020, then as a 
global pandemic on March 11, 2020, the 
coronavirus infectious disease, or popularly 
known as COVID-19, has not shown any signs 
of its disappearance. The number of cumulative 
active cases and deaths keep climbing up, 
especially in Indonesia. On February 11, 2021, 
the confirmed case has reached 1.191.990 cases 
with 32.381 deaths in Indonesia.1  
Although dominantly causing damage to the 
lung, the clinical features of COVID-19 show 
similarity with other infectious diseases like 
dengue infection or malaria. Fever, mild cough, 
headache, arthralgia, myalgia, fatigue, nausea, 
and sometimes vomiting, can be found as 
typical symptoms in these three diseases that 
bring patients to seek medical advice. 
Laboratory finding like thrombocytopenia is 
also common in these diseases and sometimes 
leads to misdiagnosis. High suspicion of 
COVID-19 nowadays has also made other 
infectious diseases as other differential 
diagnoses of fever were left behind for further 
investigations. The holistic approach including 
careful anamnesis especially traveling history, 
the onset and pattern of fever, physical 
examination, and choosing appropriate 
laboratory investigations should be applied. 
 
 
2. Case report 
 
A 31-year-old man, presented to the emergency 
unit in the hospital with high-grade fever 
accompanied by chill, shiver, headache, mild 
cough, mild diarrhea, and nausea. The fever 
started seven days before, at night, right after he 
arrived home after traveling by plane from 
Timika, Papua. He stayed and worked there for 
two months on a construction project.  On the 
second day from the onset of fever, he went to 
the secondary level hospital and was admitted 
there and diagnosed with dengue fever because 
of low platelet count. From day 4 until day 6 
from the onset of fever, the temperature was 
normal and the platelet count was around 60 – 
75 x 103/µL. He was discharged on day 7 with 
a diagnosis of ITP (Idiopathic 
thrombocytopenic purpura) and was planned 
for further workup from the outpatient clinic.  
But at night, the fever, chill, and shiver 
returned, he then went to our tertiary level 
hospital. He had no history of chronic medical 
conditions. 
 At the current presentation, the temperature 
was 39.0 C, respiratory rate was 20 x/m, heart 
rate was 92 x/m, normal blood pressure with 
97% oxygen saturation on room air.  The 
physical examination revealed relatively 
normal, no hepatosplenomegaly. Initial 
laboratory examination showed significant 
thrombocytopenia with platelet count 69 x 
103/µL, leucocytosis with WBC count 15.52 x 
109/L, 85% of neutrophil and 9% of 
lymphocyte, and elevated level of C-reactive 
protein (CRP, 96 mg/L). According to the 
patient, when he traveled by plane, the result of 
the rapid antibody test for SARS-CoV-2 was 
non-reactive both for IgM dan IgG. He was sent 
to the isolation ward for COVID-19 because his 
condition met the criteria for a suspected case 
of SARS-CoV-2 infection. The PCR SARS-
CoV-2 swab test was ordered as well as thick 
and thin blood film tests for malaria and rapid 
antigen test for malaria were also performed. 
Malaria smear was positive for Plasmodium 
falciparum, with ring form trophozoite and 
banana-shaped gametocyte. The rapid antigen 
test was also positive for Plasmodium 
falciparum. The nasopharyngeal PCR for 
SARS-CoV-2 was also positive with a CT value 
of 13.52 detected for gene orf1ab. Further 
laboratory examination showed slight elevation 
of creatinine (1,24 mg/dL) and total bilirubin 
1,50 mg/dL, and normal PO2/FiO2 (448,4 
mmHg). Chest X-ray revealed pneumonia. 
Dihydroartemisinin-piperaquine for three 
days and primaquine for one day were 
administered to treat malaria. Favipiravir 1600 
mg bid day 1 – 600 mg bid day 2-5 orally, and 
azithromycin 500 mg orally, both for five days, 
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as a treatment protocol for COVID-19, were 
given to the patients, along with vitamin C 1000 
mg orally, N-acetylcysteine 200 mg three times 
daily orally. In follow-up laboratory 
examination, day 1 after administration of 
antimalarials and antivirals, D-dimer level was 
high, >20,00 mg/L with normal fibrinogen, 
while platelet count dropped to the level of 38 
x 103/µL and CRP increased (150 mg/dL). 
Plasmodium falciparum was still detected. The 
patient was in a hypercoagulable state and 
anticoagulant therapy enoxaparin 40 mg 
subcutaneous was considered to be given in 
caution if D-dimer did not decrease with 
definitive therapy with antimalarials and 
antiviral because platelet was very low. On 
further follow-up,  D-dimer decreased to 11,60 
mg/L then to 1,22 mg/L on day 4 after definitive 
treatment started. The platelet was 63 x 103/µL, 
and enoxaparin was postponed. Blood smear 
evaluation on day 4 showed negative 
Plasmodium falciparum. The patient did not 
experience fever, nausea, and headache 
anymore, he was discharged from the hospital 
for self-isolation from COVID-19 on day 7. 
On day 14, the patient came to the outpatient 
clinic for follow-up. He complained of no 
symptoms. The platelet level returned to 
normal, 407 x 103/µL and Plasmodium 
falciparum was not detectable on the blood 
smear. The PCR SARS CoV-2 swab test was 
not evaluated and he was recovered from 
COVID-19 after completing self-isolation.  
 
   
3. Discussion 
 
Thrombocytopenia is frequently found as a 
result of viral infection. In a non-endemic area 
of malaria, like Palembang, South Sumatera, an 
acute febrile illness with thrombocytopenia is 
associated with dengue infection, especially 
when the platelet count is below 150.000 per 
microliter of blood. But in the clinical course of 
dengue infection, the recovery phase is 
characterized by no fever, the platelet count 
increases and returns to normal, and 
reabsorption of fluid overload on days 6-7 since 
the onset of fever.2 Other diagnoses besides 
dengue infection should be considered 
whenever fever and low platelet count after day 
7 persist.    
Thrombocytopenia in malaria has been 
shown in many studies, ranging from 24-94%  
as reviewed by Lacerda et al, 2011.3 Recent 
study conducted by Gupta et al, in 2013 
revealed 100 cases of thrombocytopenia in 130 
malaria vivax positive patients. While from 90 
malaria falciparum-positive patients, 
thrombocytopenia was seen in 70 cases. In both 
malaria, the platelet count was mostly between 
25.000 and 50.000.4 Although 
thrombocytopenia is not regarded as a clinical 
manifestation of severe malaria, some studies 
reported its association with severe malaria, 
especially in the pediatric population.3,5 Several 
mechanisms were proposed as the pathogenesis 
of malarial thrombocytopenia, including 
coagulation disturbances, splenomegaly, bone 
marrow alterations, antibody-mediated platelet 
destruction, oxidative stress, and platelet 
aggregation.3 Despite its frequent occurrence, 
the severe bleeding incidence is relatively low, 
probably because of the enhancement of 
hemostatic responses by hyperactive platelets. 
Another possible mechanism is that larger 
platelets as a compensation for low platelets in 
the periphery can preserve primary hemostasis 
and avoid severe bleeding.3,4,6    
Thrombocytopenia itself is one of the 
hematological changes commonly found in 
COVID-19, together with reduced lymphocyte 
count and elevated D-dimer level. The 
mechanisms of thrombocytopenia in COVID-
19 patients are described in several hypotheses. 
It is speculated that hematopoiesis in the bone 
marrow can be inhibited through certain 
receptors by SARS-CoV-2. The destruction of 
the hematopoietic progenitor cells in the bone 
marrow of patients with SARS-CoV-2 
pneumonia is speculated to happen after the 
cytokine storm. These mechanisms lead to 
decreased primary platelet production. After 
the storm, many blood cells are swallowed, then 
peripheral blood platelet count decreases. 
COVID-19 may also increase levels of 
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autoantibodies and immune complexes, 
resulting in specific destruction of platelets by 
the immune system. Platelet consumption is 
also increased. In COVID-19 lung tissues and 
pulmonary endothelial cells are damaged. This 
then activates the aggregation of platelets to 
form microthrombi. It is supported by the 
finding that most patients with COVID-19 have 
thrombocytopenia together with elevated D-
dimer levels and impaired coagulation time.7  
In this patient, besides low platelet count, a 
high D-dimer level was also found. This finding 
is in line with the above statement. COVID-19 
can induce pro-coagulant state, as indicated by 
increased D-dimer and fibrin degradation 
product levels, and prolonged prothrombin time 
and these are associated with a poor prognosis. 
Malaria itself also associated with a a pro-
coagulant state, with activation of the 
coagulation cascade, mediated by TNF-alpha 
and IL-6. The complications of 
microthrombosis are most commonly 
described. If bleeding and DIC are seen, they 
are associated with high mortality. Another 
mechanism proposed which can promote a pro-
coagulant state is the lysis of activated platelets, 
along with the release of tissue factor from 
damaged vascular endothelial cells, and this is 
similar to in COVID-19. Thus, greater degrees 
of coagulopathy and more severe disease with 
poor prognosis should be anticipated in malaria 
and COVID-19 co-infection rather than either 
infection alone.8,9  Fortunately, there was no 
bleeding or thrombosis incidence happened in 
this patient. After concurrent antimalarial 
therapy with dihydroartemisinin-piperaquine-
primaquine and antiviral therapy with 
favipiravir, the patient showed clinical and 
laboratory improvement.   
The source of malaria infection was 
suspected as an imported case from Papua since 
Palembang itself is not a malaria-endemic 
region. While the source of COVID-19 
infection is still confusing. Whether it was 
acquired during the patient’s travel from Papua 
to Palembang, or during the  previous 
hospitalization for suspected dengue fever a 
week earlier.    
The case of COVID-19 and malaria co-
infection with thrombocytopenia was rare to 
find. The similar case was published by Sardar 
et al, 2020, in Doha, Qatar, of a man with 
jaundiced suffering from COVID-19 and 
Plasmodium vivax malaria co-infection.10 In 
Indonesia, similar case was reported by Junaedi 
M et al, 2020 from Makassar. He reported a 
woman who previously lived in Papua with 
severe malaria falciparum and COVID-19 co-
infection and was successfully treated with 





Figure 1. Banana-shaped gametocyte (black 
arrow)of Plasmodium falciparum from the 
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Figure 2. The chest X-ray shows bilateral 




The co-infection of malaria and COVID-19 is 
very likely to happen and should be considered 
especially in patients with a traveling history 
from the malaria-endemic region and with 
suggestive symptoms for both conditions such 
as fever, fatigue and headache. Laboratory tests 
for both malaria and COVID-19 should be 
performed then to minimize the potential of 
missing either of them.12 Although 
thrombocytopenia and hypercoagulant state are 
common findings in malaria and COVID-19 
and associated with poor prognosis, appropriate 
therapy at the right time for both infections can 
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